Clinical Trial Update: Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial [Phase 2, Phase 3]

View source ↗

Summary

A pragmatic Phase 2/3 trial evaluating mepolizumab for COPD patients with eosinophilia has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Eosinophilia

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: University of Leicester | Conditions: COPD, Eosinophilia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-04-24